“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Down-Regulation of Phosphatidylinositol 3'-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer

(2008) D. Generali et al.   CLINICAL CANCER RESEARCH

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

(2008) Grazia Arpino et al.   ENDOCRINE REVIEWS

Targeted therapies in breast cancer: Where are we now?

(2008) Serena Di Cosimo et al.   EUROPEAN JOURNAL OF CANCER

S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation

(2008) Rachel L. Yamnik et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer

(2008) Daniele Generali et al.   JOURNAL OF CLINICAL ONCOLOGY